Tuesday, March 28, 2017 8:26:05 PM
" Gastro retentive drug delivery systems provide dosage forms with longer residence time in the stomach and sustained-release behavior, which can improve bioavailability as well as acting locally on the stomach. Increasing gastric residence time can be achieved either by floating systems that cause buoyancy above gastric fluid, high-density systems that sink to the bottom of the stomach, bioadhesive systems that adhere to mucosal surfaces, or by expandable systems that have limited emptying through the stomach pylorus due to swelling or unfolding to a larger size.
https://www.dovepress.com/design-and-evaluation-of-effervescent-floating-tablets-based-on-hydrox-peer-reviewed-fulltext-article-DDDT
Ran across something interesting while investigating....
Perhaps this could further improve the efficacy of B-OM. I believe it was a Brilacidin (PMX-30063) formulation for oral applications...
Activity of Potent and Selective Host Defense Peptide Mimetics in Mouse Models of Oral Candidiasis
"In order to examine the potential of these compounds as a treatment for oral candidiasis, an optimal delivery system was developed. A hydroxyethylcellulose gel (Natrosol) was selected due to its neutral charge and its current use in many oral applications. Compounds 2, 4, and 5 were dissolved in Natrosol and overlaid with a suspension of C. albicans GDH2346. The results shown in Fig. 3 indicate a rapid killing of Candida in the medium after exposure to the gel. A sampling of the medium applied to the gel indicated a rapid elution of the compounds into the medium (data not shown). This suggests that the observed killing is due to the interaction of the compound with the Candida in the liquid medium, rather than to a direct interaction with the gel. These results indicate that the Natrosol hydrogel represents an efficient method to deliver the antifungal compounds into the saliva for substantive treatment."
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f80229de4bb7e7c4551dd/1480556579601/Antimicrob.-Agents-Chemother.-2014-Ryan-3820-7.pdf
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM